113P Pembrolizumab in microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) advanced solid tumors: An update of the phase II KEYNOTE-158 trial

Pembrolizumab provides durable tumor responses in patients (pts) with advanced MSI-H/dMMR solid tumors. Data from the multicohort KEYNOTE-158 (NCT02628067) trial supported approval by FDA of pembrolizumab for unresectable or metastatic MSI-H/dMMR advanced solid tumors that progressed on prior therapy. Here we present data from 373 pts with MSI-H/dMMR tumors with a median follow-up approximate of 54 months.